Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bortezomib in Reduced-Intensity Allo-SCT for High-Risk Multiple Myeloma
NCT00564200Phase 2Completed
- Sponsor
- Fundación PETHEMA
- Start
- Nov 2007
- Primary completion
- Jul 2014
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of bortezomib in multiple myeloma (MM), sponsored by Fundación PETHEMA. Started Nov 2007; status: completed.
02
Drugs
bortezomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT00564200.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00564200.